STK11 deletion + KRAS mutation
|
LUAD
|
STK11 deletion + KRAS mutation
|
LUAD
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
STK11 deletion + KRAS mutation
|
LUAD
|
STK11 deletion + KRAS mutation
|
LUAD
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
STK11 deletion + KRAS mutation
|
NSCLC
|
STK11 deletion + KRAS mutation
|
NSCLC
|
MEK inhibitor + sotorasib Sensitive: D – Preclinical
|
MEK inhibitor + sotorasib Sensitive: D – Preclinical
|
STK11 deletion + KRAS mutation
|
NSCLC
|
STK11 deletion + KRAS mutation
|
NSCLC
|
AMG 176 + MEK inhibitor Sensitive: D – Preclinical
|
AMG 176 + MEK inhibitor Sensitive: D – Preclinical
|